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amount. The achievement of budgetary targets was a
qualifying (i.e., mandatory) criterion for incentive 
payments in 59% of PCTs, but considerable discretion
was available. The therapeutic targets generally made
sense and included the promotion of generics and the
encouragement of appropriate prescribing of drugs that
are widely used (e.g., antibacterials). The schemes also
embodied different ways of assessing whether targets
were achieved, some using an “all or nothing” assess-
ment, others using a points system relating to the extent
to which various targets were achieved. CONCLU-
SIONS: Prescribing incentive schemes currently used by
PCTs in England offer modest ﬁnancial incentives to GPs.
Although the selection of prescribing targets generally
makes sense, the qualifying criteria and methods of
assessing target achievement are quite variable and non-
speciﬁc. Whilst not providing strong incentives to GPs,
they may make a contribution by signaling to prescribers
which elements of prescribing are important.
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OBJECTIVES: Generic competition has intensiﬁed in the
U.S. prescription drug industry. We seek to understand
the process of generic competition by developing a model
for the determinants of generic entry, prices, and gener-
ics’ market share. METHODS: We develop a simultane-
ous equation estimation framework to examine the
interaction among generic entry, prices, and market
shares. The model is estimated on a panel data sample
containing 40 brand name drugs that faced ﬁrst generic
competition during the period July 1992 through January
1998. The data period for each drug spans 36 months
before and 36 months after generic entry. We use appro-
priate estimation method for panel data. RESULTS: We
ﬁnd that: 1) generic entry is positively related to pre-entry
market size of the brand, but negatively inﬂuenced by the
number and the market share of the generic incumbents,
and the presence of entry-restricting conditions; 2) 
generics’ share is inﬂuenced positively by the number of
generics and HMO coverage rate, but negatively by the
generic-to-brand price ratio and the presence of entry-
restricting conditions; 3) the generic-to-brand price ratio
is larger in cases where entry-restricting conditions exist,
but smaller where there are more generic competitors or
where generics’ share is larger. Additionally, the generic-
to-brand price ratio is lower for blockbuster drugs; and
4) on average, brand prices respond to generic entry—the
inﬂation-adjusted rate of brand price change is found 
to be signiﬁcantly lower after generic entry. Finally, we
demonstrate the accuracy of our estimation model by pre-
dicting the out-of-sample experience of the drug Prozac
(ﬂuoxetine). CONCLUSIONS: Generic share inﬂuences
and is inﬂuenced by price, while the number of generic
entrants is a key determinant of generic share and generic-
to-brand price ratio. Generic competition is found to be
particularly intense for blockbuster drugs, which experi-
ence signiﬁcantly more generic entrants, price erosion and
generic penetration than other drugs.
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Historical drug sales data are frequently used for formu-
lary budget impact analyses of new pharmaceuticals.
Growth projections are either empirical or based on
simple linear regression calculations. Recent evidence
indicates that the aggregate life cycle of pharmaceuticals
approximates an “inverted U” distribution, however
information about life cycle by therapeutic category is 
not available. OBJECTIVES: Determine functional data
form to guide statistical modeling of the sales life cycle 
of pharmaceutical products, by therapeutic category.
METHODS: Pharmaceutical sales data for 1992 to 2001
were obtained from IMS Canada and classiﬁed as to type
(prescription, over the counter, diagnostic); formulation
(tablets/capsules, injectable); release mechanism (regu-
lar, extended/sustained); compounding (single, multiple
active drugs); research origin (branded, generic) and ther-
apeutic category. Records meeting the following criteria
were included in the initial analysis: prescription,
branded, tablets/capsules, and single compounds. Using
the date of ﬁrst sale, the number of months on the market
was calculated for each compound by calendar year. 
Sales data were adjusted for inﬂation using the Canadian
consumer price index (1992 = 1.00) and expressed per
1000 population (2001 Canadian census). Detailed IMS
therapeutic categories were consolidated into 59 cate-
gories. Linear regression and graphical examination
focused on the ten top selling categories. RESULTS:
For all drugs, linear regression explained only 3% of the
variance in yearly sales and showed no signiﬁcant dif-
ference by release mechanism. Graphical examination
revealed two consistent trends: 1) A sharp rise in sales
peaking at approximately 100 months followed by a slow
decay and 2) three patterns of sales: a) 2–5 “super
sellers”; b) 6–10 “above average sellers”; and c) the
majority being average sellers. CONCLUSIONS: Drug
sales are non-linear over time and are characterized by
three distinct patterns. Future models will utilize non-
linear techniques and incorporate number of branded
compounds, number and timing of generic compounds
and market share.
